Dr. Marty Makary

And we live in a modern world where we have computational modeling using AI that can evaluate a molecule and predict its toxicity in humans better than the animal testing. We also have something called organ-on-a-chip technology where, say, liver cells are grown in the lab.

Yeah, I personally cannot eat liver. I've operated on the liver too much. Oh, God. That's one food I cannot do. No one wants organ-on-a-chip. Yeah, organ-on-a-chip. So in the lab, they grow these cells. and then they introduce the drug. And you can actually see whether or not it injures the cells better than if you inject some bunny rabbit that is not gonna talk to you and say my liver hurts.

Yeah, I personally cannot eat liver. I've operated on the liver too much. Oh, God. That's one food I cannot do. No one wants organ-on-a-chip. Yeah, organ-on-a-chip. So in the lab, they grow these cells. and then they introduce the drug. And you can actually see whether or not it injures the cells better than if you inject some bunny rabbit that is not gonna talk to you and say my liver hurts.

Yeah, I personally cannot eat liver. I've operated on the liver too much. Oh, God. That's one food I cannot do. No one wants organ-on-a-chip. Yeah, organ-on-a-chip. So in the lab, they grow these cells. and then they introduce the drug. And you can actually see whether or not it injures the cells better than if you inject some bunny rabbit that is not gonna talk to you and say my liver hurts.

So these new technologies have the promise of replacing some of this routine animal testing. You would cut six months out of that approval process. You lower R&D costs for pharma companies and inventors, which could lower drug prices for everyday Americans. And it reduces animal use. There's too much animal use.

So these new technologies have the promise of replacing some of this routine animal testing. You would cut six months out of that approval process. You lower R&D costs for pharma companies and inventors, which could lower drug prices for everyday Americans. And it reduces animal use. There's too much animal use.

So these new technologies have the promise of replacing some of this routine animal testing. You would cut six months out of that approval process. You lower R&D costs for pharma companies and inventors, which could lower drug prices for everyday Americans. And it reduces animal use. There's too much animal use.

Yeah, we're bringing in a team that is really exciting. They're going to introduce AI into the review process to help the reviewer, to make the reviewer's work stream much more streamlined and summarize things. There are parts of the drug application that are so perfunctory, that are outdated, that could be streamlined, that could be abstracted with AI technology. to help the reviewer.

Yeah, we're bringing in a team that is really exciting. They're going to introduce AI into the review process to help the reviewer, to make the reviewer's work stream much more streamlined and summarize things. There are parts of the drug application that are so perfunctory, that are outdated, that could be streamlined, that could be abstracted with AI technology. to help the reviewer.

Yeah, we're bringing in a team that is really exciting. They're going to introduce AI into the review process to help the reviewer, to make the reviewer's work stream much more streamlined and summarize things. There are parts of the drug application that are so perfunctory, that are outdated, that could be streamlined, that could be abstracted with AI technology. to help the reviewer.

Why does it take 10 years to bring a drug to market in the United States? Because of the regulatory steps. I mean, people are dying. People need cures and meaningful treatments. And my predecessor in this role was focused, as he stated, his number one goal was fighting misinformation. Well, our number one goal is delivering cures and meaningful treatments and healthier foods for Americans.

Why does it take 10 years to bring a drug to market in the United States? Because of the regulatory steps. I mean, people are dying. People need cures and meaningful treatments. And my predecessor in this role was focused, as he stated, his number one goal was fighting misinformation. Well, our number one goal is delivering cures and meaningful treatments and healthier foods for Americans.

Why does it take 10 years to bring a drug to market in the United States? Because of the regulatory steps. I mean, people are dying. People need cures and meaningful treatments. And my predecessor in this role was focused, as he stated, his number one goal was fighting misinformation. Well, our number one goal is delivering cures and meaningful treatments and healthier foods for Americans.

That is our focus. And so you've heard about consolidation or changes or cuts at the FDA. Those were not cuts to scientists or reviewers or inspectors. Absolutely none. They were cuts to communications staff, FDA's lobbyists to Congress, and to the IT systems here where there's a lot of opportunity for efficiencies.

That is our focus. And so you've heard about consolidation or changes or cuts at the FDA. Those were not cuts to scientists or reviewers or inspectors. Absolutely none. They were cuts to communications staff, FDA's lobbyists to Congress, and to the IT systems here where there's a lot of opportunity for efficiencies.

That is our focus. And so you've heard about consolidation or changes or cuts at the FDA. Those were not cuts to scientists or reviewers or inspectors. Absolutely none. They were cuts to communications staff, FDA's lobbyists to Congress, and to the IT systems here where there's a lot of opportunity for efficiencies.

There is a massive growth of FDA employees under the Biden administration. And when the media reports that there were cuts, which many were early retirements, people took early retirement. None were to scientific reviewers or inspectors or law enforcement at the FDA. They were to IT communications, legislative affairs.

There is a massive growth of FDA employees under the Biden administration. And when the media reports that there were cuts, which many were early retirements, people took early retirement. None were to scientific reviewers or inspectors or law enforcement at the FDA. They were to IT communications, legislative affairs.

There is a massive growth of FDA employees under the Biden administration. And when the media reports that there were cuts, which many were early retirements, people took early retirement. None were to scientific reviewers or inspectors or law enforcement at the FDA. They were to IT communications, legislative affairs.

And so what you're not hearing in the mainstream media is that there was a 100% increase in the number of FDA employees since 2006.